Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 7/2013

01-07-2013 | Brief Report

Hemagglutination mediated by the spike protein of cell-adapted bovine torovirus

Authors: Kozue Shimabukuro, Makoto Ujike, Toshihiro Ito, Hiroshi Tsunemitsu, Hitoshi Oshitani, Fumihiro Taguchi

Published in: Archives of Virology | Issue 7/2013

Login to get access

Abstract

Bovine torovirus (BToV)-Aichi, recently isolated in cultured cells, showed hemagglutination (HA) activity, although the virus has a truncated hemagglutinin-esterase (HE) protein, judging from its gene structure, indicating the existence of another viral protein with HA activity. We examined whether the spike (S) protein possesses HA activity. A BToV antiserum used in this study, reactive to S but not to HE, inhibited HA activity. Furthermore, cells infected with BToV and those expressing S showed hemadsorption (HAD) activity, which was inhibited by the anti-BToV serum; however, HAD activity by expressed HE was not blocked. These data indicate that the S protein of BToV-Aichi is responsible for its HA activity.
Literature
1.
Aita T, Kuwabara M, Murayama K, Sasagawa Y, Yabe S, Higuchi R, Tamura T, Miyazaki A, Tsunemitsu H (2012) Characterization of epidemic diarrhea outbreaks associated with bovine torovirus in adult cows. Arch Virol 157:423–431PubMedCrossRef
2.
Brown DW, Beards GM, Flewett TH (1987) Detection of Breda virus antigen and antibody in humans and animals by enzyme immunoassay. J Clin Microbiol 25:637–640PubMed
3.
Cavanagh D, Davis P (1986) Coronavirus IBV: removal of spike glycopolypeptide S1 by urea abolished infectivity and haemagglutination but not attachment to cells. J Gen Virol 67:1143–1148
4.
de Groot RJ (2006) Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. Glycoconj J 23:59–72PubMedCrossRef
5.
Gagneten S, Gout O, Dubois-Dalcq M, Rottier P, Rossen J, Holmes KV (1995) Interaction of mouse hepatitis virus (MHV) spike glycoprotein with receptor glycoprotein MHVR is required for infection with an MHV strain that expresses the hemagglutinin-esterase glycoprotein. J Virol 69:889–895PubMed
6.
Hirano N, Murakami N, Taguchi F, Fujiwara K, Matumoto M (1981) Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes. Arch Virol 70:69–73PubMedCrossRef
7.
Ito T, Katayama S, Okada N, Masubuchi K, Fukuyama S, Shimizu M (2010) Genetic and antigenic characterization of newly isolated bovine toroviruses from Japanese cattle. J Clin Microbiol 48:1795–1800PubMedCrossRef
8.
Ito T, Okada N, Fukuyama S (2007) Epidemiological analysis of bovine torovirus in Japan. Virus Res 126:32–37PubMedCrossRef
9.
Kazi L, Lissenberg A, Watson R, de Groot RJ, Weiss SR (2005) Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence. J Virol 79:15064–15073PubMedCrossRef
10.
11.
Kremple C, Schultze B, Laude H, Herrler G (1997) Point mutations in the S protein connect the sialic aciding activity with the enteropathogenicity of transmissible gastroenteritis coronavirus. J Virol 71:3285–3287
12.
Kuwabara M, Wada K, Maeda Y, Miyazaki A, Tsunemitsu H (2007) First isolation of cytopathogenic bovine torovirus in cell culture from a calf with diarrhea. Clin Vaccine Immunol 14:998–1004PubMedCrossRef
13.
Luytjes W, Bredenbeek PJ, Noten AF, Horzinek MC, Spaan WJ (1988) Sequence of mouse hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C virus. Virology 166:415–422PubMedCrossRef
14.
15.
Schultze B, Gross H-J, Brossmer R, Herrler G (1991) The S protein of bovine coronavirus is a hemagglutinin recognizing 9–0-acetylated sialic acid as a receptor determinant. J Virol 65:6232–6237PubMed
16.
Shirato K, Maejima M, Matsuyama S, Ujike M, Miyazaki A, Takeyama N, Ikeda H, Taguchi F (2011) Mutation in the cytoplasmic retrieval signal of porcine epidemic diarrhea virus spike (S) protein is responsible for enhanced fusion activity. Virus Res 161:188–193PubMedCrossRef
17.
Snijder EJ, Horzinek MC (1993) Toroviruses: replication, evolution and comparison with other members of the coronavirus-like superfamily. J Gen Virol 74:2305–2316PubMedCrossRef
18.
Snijder EJ, den Boon JA, Horzinek MC, Spaan WJ (1991) Comparison of the genome organization of toro- and coronaviruses: evidence for two nonhomologous RNA recombination events during Berne virus evolution. Virology 180:448–452PubMedCrossRef
19.
Taguchi F, Massa P, ter Meulen V (1986) Characterization of a variant virus isolated from neural cell culture after infection of mouse coronavirus JHMV. Virology 155:267–270PubMedCrossRef
20.
Vlasak R, Luytjes W, Spaan W, Palease P (1988) Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA 85:4526–4529PubMedCrossRef
21.
Weiss M, Steck F, Horzinek MC (1983) Purification and partial characterization of a new enveloped RNA virus (Berne virus). J Gen Virol 64:1849–1858PubMedCrossRef
22.
Wood GN, Reed DE, Runnels PL, Herrig MA, Hill HT (1982) Studies with an unclassified virus isolated from diarrheic calves. Vet Microbiol 7:221–240CrossRef
23.
Yokomori K, Baker SC, Stohlman SA, Lai MM (1992) Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus. J Virol 66:2865–2874PubMed
Metadata
Title
Hemagglutination mediated by the spike protein of cell-adapted bovine torovirus
Authors
Kozue Shimabukuro
Makoto Ujike
Toshihiro Ito
Hiroshi Tsunemitsu
Hitoshi Oshitani
Fumihiro Taguchi
Publication date
01-07-2013
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 7/2013
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-013-1636-4

Other articles of this Issue 7/2013

Archives of Virology 7/2013 Go to the issue

Annotated Sequence Record

The complete genomic sequence of a novel mycovirus from Rhizoctonia solani AG-1 IA strain B275

Brief Report

Construction of an infectious cDNA clone of radish mosaic virus, a crucifer-infecting comovirus

Original Article

Baculovirus replication induces the expression of heat shock proteins in vivo and in vitro

Annotated Sequence Record

Molecular characterisation of two divergent variants of grapevine leafroll-associated virus 3 in New Zealand

Erratum

Erratum to: Genetic characterization of betanodavirus isolates from Asian seabass Lates calcarifer (Bloch) in India

Original Article

Microarray analysis of differentially expressed transcripts in porcine intestinal epithelial cells (IPEC-J2) infected with porcine sapelovirus as a model to study innate immune responses to enteric viruses
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits